A Phase 2 Study of VP-16 , Ifosfamide , and Cisplatin ( VIP ) Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Limited Small Cell Lung Cancer.
- Author:
Seok Ah IM
1
;
Moon Hee LEE
;
Chul Won JUNG
;
Dae Seog HEO
;
Yung Jue BANG
;
Young Soo SHIM
;
Chan Il PARK
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Limited stage small cell lung cancer;
Thoracic irradiation;
Etoposide (VP-16);
Ifosfamide;
Cisplatin
- MeSH:
Bone Marrow;
Cisplatin*;
Cranial Irradiation;
Disease-Free Survival;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide*;
Follow-Up Studies;
Humans;
Ifosfamide*;
Leukopenia;
Lost to Follow-Up;
Mesna;
Nausea;
Peripheral Nervous System Diseases;
Seoul;
Sepsis;
Small Cell Lung Carcinoma*;
Thrombocytopenia;
Vomiting
- From:Journal of the Korean Cancer Association
1999;31(2):306-312
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: A phase II study of etoposide, ifosfamide, cisplatin combination chemotherapy and concurrent thoracic irradiation in patients with untreated limited small cell lung cancer (SCLC) was conducted to assess toxicities, response rate, response duration, and median survival. MATERIALS AND METHODS: Patients with histologically confirmed SCLC with a ECOG criteria 2 and adequate renal function and bone marrow reserve were eligible. Each cycle consisted of VP-16 100 mg/m i.v, days 1-3, ifosfamide 1,200 mg/m i.v. days 1-3 with Mesna, and cisplatin 30 mg/m i.v. days 1-3. Cycles were repeated every 21 days. Concutrent thoracic itradiation was given as total 40-45 Gy for 4-5 weeks beginning within 24 hours of the third cycle. Patients with complete remission received prophylactic cranial irradiation after the 6th cycle. RESULT: Forty two patients with limited SCLC were treated at Seoul National University Hospital between December 1993 and August 1996. Three patients were not evaluable because of lost to follow up (2 patients) and one treatment-related early death. Of 39 evaluable patients, responses were seen in 38 (97%) patients including 22 (56%) complete responses and 16 (41%) partial responses. The median remission duration was 65 wks. The median disease free survival was 60 wks. The median overall survival was not reached and 2-year survival was 69% with median duration of follow up of 63.5 wks. Hematologic side effects (WHO Gr>III/IV) of evaluable 228 cycles of chemotherapy were leukopenia in 34%, thrombocytopenia in 16%. One patient expired after prolonged leukopenia and sepsis. Nonhematologic side effects (WHO Gr>II) included nausea and vomiting (17%) and peripheral neuropathy (2%). CONCLUSION: VIP combination chemotherapy with concurrent thoracic irradiation is effective and tolerable in limited SCLC.
